Ventra Health, Inc. – Trademark Portfolio
Entity Type: 03
Ventra Health, Inc. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 4 trademarks are registered and 1 is pending. Notable registered marks include VCHART, VENTRA, and VSIGHT. The owner is based in Dallas, TX.
5001 LBJ Freeway, Suite 320
Dallas, TX 75244
Showing of trademarks Trademarks
Trademark Classifications
Ventra Health, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Ventra Health, Inc. have?
Ventra Health, Inc. has 6 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 1 abandoned.
What trademark classes does Ventra Health, Inc. file in?
Ventra Health, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 35 (Advertising & Business), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Ventra Health, Inc.'s most well-known trademarks?
Ventra Health, Inc.'s registered trademark portfolio includes well-known marks such as VCHART, VENTRA, and VSIGHT. These are among 4 currently registered trademarks in the portfolio.
What is Ventra Health, Inc.'s trademark registration success rate?
Ventra Health, Inc. has a 80% trademark registration rate, with 4 out of 5 resolved applications resulting in successful registration. Currently, 1 application is pending review.